Follicular T-Cell Lymphoma
Associated Genetic Biomarkers
NCI Definition: A variant of peripheral T-cell lymphoma, not otherwise specified. It is characterized by the formation of nodular lymphocytic aggregates of atypical clear cells, either within the lymphoid follicles in a background of progressive transformation of germinal centers, or in the perifollicular areas. 
There are 7 clinical trials for follicular T-cell lymphoma, of which 7 are open and 0 are completed or closed. Of the trials that contain follicular T-cell lymphoma as an inclusion criterion, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (2 open), and 2 are phase 3 (2 open).
CD38 and TNFRSF8 are the most frequent gene inclusion criteria for follicular T-cell lymphoma clinical trials .
Azacitidine, nampt inhibitor ot-82, and brentuximab vedotin are the most common interventions in follicular T-cell lymphoma clinical trials.
Significant Genes in Follicular T-Cell Lymphoma
ALK is an inclusion eligibility criterion in 1 clinical trial for follicular T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ALK status and follicular T-cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.